Intercept Pharmaceuticals, Inc. (ICPT)

14,77 -0,04 (-0,27%) Al cierre: 01:00PM EST

Intercept Pharmaceuticals, Inc.

10 Hudson Yards
37th Floor
New York, NY 10001
United States
646 747 1000
https://www.interceptpharma.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 437

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Jerome B. Durso	Pres, CEO & Director	1,16M	N/A	1968
Mr. Andrew Saik	Chief Financial Officer	485,07k	N/A	1969
Mr. Rocco Venezia	Chief Accounting Officer & Treasurer	660,62k	N/A	1976
Mr. Jared M. Freedberg J.D.	Gen. Counsel	691,46k	N/A	1968
Dr. M. Michelle Berrey M.D., M.P.H., MPH.	Pres of R&D and Chief Medical Officer	732,13k	N/A	1967
Mr. Nareg Sagherian	Exec. Director of Global Investor Relations	N/A	N/A	N/A
Mr. David Ford	Chief HR Officer	N/A	N/A	1970
Dr. Mark Pruzanski M.D.	Founder, Advisor & Director	N/A	N/A	1968
Ms. Linda M. Richardson	Exec. VP & Chief Commercial Officer	N/A	N/A	1964
Paul Nitschmann	Sr. VP of Regulatory Affairs	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Gobierno corporativo

El ISS Governance QualityScore de Intercept Pharmaceuticals, Inc., a día 1 de noviembre de 2022, es 4. Las puntuaciones base son Auditoría: 8; Tablero: 2; Derechos de los accionistas: 6; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.